Stock comparison
JOHNSON & JOHNSON is 40.3x more valuable than Jazz Pharmaceuticals plc by market capitalization ($623.71 B vs $15.49 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
JNJ is larger
JOHNSON & JOHNSON is 40.3x more valuable than Jazz Pharmaceuticals plc by market capitalization ($623.71 B vs $15.49 B).
Market value leader
JNJ
JOHNSON & JOHNSON is 40.3x more valuable than Jazz Pharmaceuticals plc by market capitalization ($623.71 B vs $15.49 B).
Revenue leader
JNJ
JAZZ: $4.27B vs JNJ: $94.19B.
Profit leader
JNJ
JAZZ: -$356.15M vs JNJ: $26.80B.
Margin leader
JNJ
JAZZ: -8.3% vs JNJ: 28.5% net margin.
| Metric | JAZZ | JNJ |
|---|---|---|
| Market cap | $15.49 B | $623.71 B |
| US-listed rank | #722 | #17 |
| Revenue (latest FY) | $4.27B | $94.19B |
| Net income (latest FY) | -$356.15M | $26.80B |
| Net margin | -8.3% | 28.5% |
| P/E (trailing FY) | - | 23.3x |
| SEC filings | 2,087 | 990 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
JOHNSON & JOHNSON is 40.3x more valuable than Jazz Pharmaceuticals plc by market capitalization ($623.71 B vs $15.49 B).
In their latest fiscal years, Jazz Pharmaceuticals plc reported $4.27B in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Jazz Pharmaceuticals plc and JOHNSON & JOHNSON, or browse the full rankings.